<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04688671</url>
  </required_header>
  <id_info>
    <org_study_id>ETX-018810-202</org_study_id>
    <nct_id>NCT04688671</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects With Diabetic Peripheral Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eliem Therapeutics (UK) Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eliem Therapeutics (UK) Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate&#xD;
      the Efficacy and Safety of ETX 018810 in Subjects with Diabetic Peripheral Neuropathic Pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Placebo-Controlled, Parallel-Group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of ETX 018810 on neuropathic pain via daily pain measurements in subjects with diabetic peripheral neuropathic pain (DPNP)</measure>
    <time_frame>baseline to Week 4</time_frame>
    <description>Change from in the weekly average of the daily pain score as derived from the subject's responses on the Pain Intensity Numerical Rating Scale (PI-NRS) a 10 point scale from 0 being the least (No Pain) to 10 being the most (Worst Possible Pain).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Diabetic Peripheral Neuropathic Pain</condition>
  <condition>Diabetic Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>ETX-018810</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ETX-018810</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>ETX-018810</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject is ≥18 and ≤75 years of age at the time of signing ICF.&#xD;
&#xD;
          -  The subject has a diagnosis of type 1 or 2 diabetes mellitus.&#xD;
&#xD;
          -  The subject has diabetic neuropathy of a symmetrical nature in the lower extremities&#xD;
             for ≥6 months to ≤10 years&#xD;
&#xD;
          -  The subject reports at least moderate pain intensity&#xD;
&#xD;
          -  The subject's onset of neuropathic pain is at least 3 months before the screening&#xD;
             visit.&#xD;
&#xD;
          -  The subject has used a stable regimen of antidiabetic agents for at least 1 month&#xD;
             before the baseline visit or has achieved adequate glycemic control through diet and&#xD;
             exercise.&#xD;
&#xD;
          -  The subject has clinical laboratory values within normal limits or abnormal values&#xD;
             that the investigator deems not clinically significant.&#xD;
&#xD;
          -  Sexually active male subjects with female partners of childbearing potential and&#xD;
             sexually active female subjects of childbearing potential must agree to practice&#xD;
             effective contraception or to remain abstinent during the study and for 4 weeks after&#xD;
             the last dose of investigational product&#xD;
&#xD;
          -  The subject is capable of giving signed informed consent and agrees to provide&#xD;
             authorization for use and release of health records.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has pain that cannot be clearly differentiated from or that could&#xD;
             interfere with the assessment of DPNP.&#xD;
&#xD;
          -  The subject has neurologic and/or circulatory disorders that are unrelated to diabetic&#xD;
             neuropathy&#xD;
&#xD;
          -  The subject has a history of hypoglycemia that disturbed consciousness or ketoacidosis&#xD;
             that required hospitalization within the 3 months before screening.&#xD;
&#xD;
          -  The subject has clinically significant and/or unstable renal, hepatic, hematologic,&#xD;
             immunologic, inflammatory/rheumatologic, respiratory, or cardiovascular disease that&#xD;
             would compromise participation in the study in the judgment of the investigator.&#xD;
&#xD;
          -  The subject has any neurological disease that could interfere with participation in&#xD;
             the study (eg, Huntington's disease, Parkinson's disease, Alzheimer's disease,&#xD;
             multiple sclerosis, seizures, epilepsy, stroke).&#xD;
&#xD;
          -  The subject has an amputation of a lower extremity. Toe amputation is allowed.&#xD;
&#xD;
          -  The subject has clinically significant abnormal electrocardiogram (ECG) findings at&#xD;
             screening or baseline.&#xD;
&#xD;
          -  The subject is likely to require major surgery during the study.&#xD;
&#xD;
          -  The subject is pregnant or lactating.&#xD;
&#xD;
          -  The subject is unwilling or unable to discontinue current medications for neuropathic&#xD;
             pain, including topical agents.&#xD;
&#xD;
          -  The subject is unable to refrain from using nonsteroidal anti-inflammatory drugs&#xD;
             (NSAIDs); antiepileptic drugs, steroids, cannabinoids, or major opioids, muscle&#xD;
             relaxants, tramadol, or tapentadol throughout the study.&#xD;
&#xD;
          -  The subject has used prohibited nonpharmacologic therapies, including acupuncture,&#xD;
             transcutaneous electrical nerve stimulation, etc, within 30 days before baseline/Day 1&#xD;
             or anticipates use of such therapies during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Head of Clinical Development Operations</last_name>
    <phone>877-834-0490</phone>
    <email>studyinfo@eliemtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CMR of Greater New Haven</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Research Coordinator</last_name>
      <phone>203-437-4373</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 25, 2020</study_first_submitted>
  <study_first_submitted_qc>December 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

